An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Number of participants with at least 1 exacerbation

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

QT interval corrected using the Fridericia formula [QTc (Frid)] - Change from baseline to end of treatment

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Total ectopic ventricular (VE) beats - number of participants with shift from normal (<50) to high (≥50) from baseline to visit 4.

Data were available for a subset of patients.

Total ectopic supraventricular (VE) beats - number of participants with shift normal (<50) to high (≥50) from baseline to visit 4.

Data were available for a subset of patients

Total ventricular runs - number of participants with shift normal (<1) to high (≥1) from baseline to week 2.

Data were available for a subset of patients.

Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered "no" to having used rescue medication that day

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered "no" to having symptoms that day

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered "no" to having symptoms and "0" to the use of rescue medication that day

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Number of participants with positive response to Item 2 in questionnaire "During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of "strongly agree" or "somewhat agree"

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Number of participants with positive response to Item 5 in questionnaire "During the past week, you were satisfied with how quickly you felt your study medication begin to work." The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of "strongly agree" or "somewhat agree"

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.

Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.

The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.